Good news every one! We are almost there. Essentialis Announces the Dosing of the First Prader-Willi Syndrome Patients in a Long-Term Extension to Clinical Trial PC025.
Patients who completed the first two phases of clinical study PC025 are currently being enrolled in a 6-month open label extension. The objective of the extension is to document the long-term therapeutic benefits of DCCR, Essentialis’ lead drug, on hyperphagia, body fat, lean body mass, aggressive, threatening and destructive behaviors and on stamina.The 6-month extension is being run by Dr. Virginia Kimonis’ team and the staff of the ICTS at the University of California, Irvine.
Link to the article: